Skip to main content

Keros Therapeutics, Inc.

KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001664710

In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Keros Therapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of KROS: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders123107−16
Shares22.4M22.9M+492.3K (+2.2%)
Value$901.0M$730.6M−$170.4M (−18.9%)

New holders (4)

Institutions that held Keros Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to KROS in Q3 2023
InstitutionSharesValue% of portfolio
Norges Bank97,400$3.11M0.00%
Gsa Capital Partners LLP17,161$547.0K0.05%
Schroder Investment Management Group7,917$253.7K0.00%
Lindbrook Capital, LLC19$6060.00%

Sold out (20)

Institutions that held Keros Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.